首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備包裝/容器

市場調查報告書

商品編碼

1917798

非PVC輸液袋市場－2026-2031年預測

Non-PVC IV Bags Market - Forecast from 2026 to 2031

出版日期: 2026年01月06日 | 出版商:

Knowledge Sourcing Intelligence | 英文 141 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

非PVC輸液袋市場預計將從2025年的22.52億美元成長到2031年的30.41億美元，維持5.13%的複合年成長率。

受靜脈輸液治療領域對更安全、更永續材料的根本性轉變的推動，非聚氯乙烯（PVC）輸液袋市場正經歷顯著成長。這些輸液袋採用聚烯（乙烯-醋酸乙烯酯共聚物、聚丙烯）、聚氨酯和聚醚碸等替代聚合物製成，旨在消除傳統聚氯乙烯（PVC）容器可能帶來的健康和環境風險。市場擴張的促進因素包括臨床需求的成長、監管措施的嚴格性以及整個產業向環保型醫療解決方案的轉型。

關鍵市場促進因素與監管催化劑

慢性疾病在全球日益加重，需要長期、高強度的靜脈輸液治療，這是成長要素。隨著癌症、慢性腎臟病（CKD）和其他嚴重的盛行率不斷上升，可靠地輸注大量液體、化療、腸外營養液和透析液至關重要。由於非聚氯乙烯（PVC）輸液袋的材料惰性以及與多種藥物製劑的相容性，它們擴大被用於這些應用，使其成為現代治療通訊協定的關鍵組成部分。

推動市場轉型的最有力、最直接的催化劑是全球針對鄰苯二甲酸二(2-乙基己基)酯 (DEHP) 的監管行動。 DEHP 是一種常用的聚氯乙烯 (PVC)塑化劑。主要市場的監管機構已發佈建議和限制，禁止在包括新生兒、孕婦和嚴重病人在內的弱勢群體中使用含 DEHP 塑化劑的醫療設備。這些法規源於人們對 DEHP 滲出物的擔憂，DEHP 滲出物可能導致代謝和發育障礙。這種監管壓力正促使醫療機構尋求更安全的替代方案，從而推動採購方式的必要轉變，並直接加速非 PVC 材質輸液容器的普及。

同時，醫療保健產業日益成長的環境和永續性意識正在推動這種材料轉變。 PVC廢棄物對環境的影響，包括回收的挑戰和潛在的毒素釋放，促使醫療保健系統優先考慮更環保的採購政策。非PVC材料通常更容易回收利用，且不含鹵代化合物，這與機構的永續性目標和企業社會責任（CSR）活動相一致——這是採購決策中一個重要的非臨床因素。

臨床和材料優勢

除了符合監管要求外，非PVC輸液袋還具有明顯的臨床和操作優勢。其材質成分通常與某些敏感藥物製劑具有更優異的相容性，包括某些脂質、紫杉烷類藥物以及其他可能與PVC產生交互作用或被PVC吸收的藥物。這降低了藥物損失、療效降低以及患者接觸滲出的塑化劑的風險。對於醫療機構而言，這意味著更高的病人安全性、更少的藥物廢棄物以及更柔軟性的藥物儲存和給藥方式。

市場挑戰與限制因素

轉型面臨諸多障礙。主要阻礙因素是非PVC材質造口袋的單位成本高於傳統PVC造口袋。這種成本差異可能成為預算緊張的醫療系統，尤其是在價格敏感型市場的一大障礙。因此，必須透過減少併發症和永續性來清晰地證明其長期價值。

此外，PVC醫療設備成熟的全球製造基礎設施使得市場快速轉型舉步維艱。替代聚合物的供應鏈必須達到類似的規模、可靠性和地理覆蓋率才能滿足全球需求。確保材料品質的穩定性以及應對檢驗新型容器-藥物組合的複雜挑戰，也需要製造商持續投入。

區域市場動態

由於嚴格的監管指導、醫療服務提供者的高度重視、有利的報銷機制以及主要市場參與者的存在，北美預計將繼續保持主導的市場佔有率。該地區對病人安全的重視，以及醫療保健領域積極的環境政策，為非PVC替代品的推廣創造了高度友善的環境。歐洲的發展軌跡與之類似，深受歐盟醫療設備法規（MDR）等全面法規和強而有力的環境法規的影響。亞太地區擁有巨大的成長潛力，這得益於不斷擴大的醫療基礎設施、日益成長的治療量以及監管標準和環保意識的逐步提高，儘管價格敏感性是一個更為突出的因素。

競爭格局與策略方向

該市場以眾多大型醫療設備製造商為特徵，這些製造商在輸液治療領域擁有豐富的產品系列。競爭主要集中在材料科學創新、藥物相容性數據、供應鏈可靠性以及提供全面的非PVC解決方案的能力。策略性舉措包括投資先進的聚合物製造技術、獲得特定高價值應用（例如腫瘤學、新生兒學）的監管核准，以及與製藥製造商合作開發相容的包裝系統。成功的關鍵在於展現臨床優勢、實現規模化成本效益，以及提供強而有力的教育支持，以幫助醫療專業人員順利過渡。

總之，在不可逆轉的監管和環境要求的推動下，非PVC輸液袋市場正從利基替代方案轉型為主流標準。其成長與慢性病管理中靜脈輸液療法的普及以及醫療產業對更安全、更永續實踐的承諾密切相關。對於業內專家而言，未來發展的關鍵在於持續改進材料技術以提高性能並降低成本，產生全面的臨床數據以支援其廣泛應用，以及應對複雜的全球監管環境以確保順利市場進入。從長遠來看，非PVC材料有望成為輸液容器的主流標準，這反映了患者照護和環境保護領域不斷變化的優先事項。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

歷史資料（2021-2025 年）和預測資料（2026-2031 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

The non-PVC IV bags market is experiencing significant growth, driven by a fundamental shift toward safer and more sustainable materials in intravenous therapy. These bags, constructed from alternative polymers such as polyolefins (ethylene-vinyl acetate, polypropylene), polyurethane, and polyethersulfone, are designed to eliminate the potential health and environmental concerns associated with traditional polyvinyl chloride (PVC) containers. The market's expansion is propelled by the convergence of rising clinical demand, stringent regulatory actions, and a broader industry movement toward eco-friendly healthcare solutions.

Core Market Drivers and Regulatory Catalysts

A primary growth driver is the escalating global burden of chronic diseases requiring intensive and long-term intravenous therapies. The rising prevalence of conditions such as cancer, chronic kidney disease (CKD), and other critical illnesses necessitates reliable, high-volume administration of fluids, chemotherapy, parenteral nutrition, and dialysis solutions. Non-PVC bags are increasingly specified for these applications due to their material inertness and compatibility with a wider range of drug formulations, making them a critical component in modern treatment protocols.

The most powerful and direct catalyst for market conversion is the global regulatory movement against di(2-ethylhexyl) phthalate (DEHP), a plasticizer commonly used to soften PVC. Regulatory bodies in major markets have issued advisories and restrictions on the use of DEHP-plasticized medical devices, particularly for vulnerable patient populations such as neonates, pregnant women, and critically ill individuals. These regulations stem from well-documented concerns over DEHP leaching, which can cause adverse metabolic and developmental effects. This regulatory pressure compels healthcare providers to seek safer alternatives, creating a mandatory shift in procurement and directly accelerating the adoption of non-PVC IV containers.

Concurrently, growing environmental and sustainability priorities within the healthcare sector are reinforcing this material transition. The environmental impact of PVC disposal, including challenges with recycling and potential release of toxins, has led healthcare systems to prioritize greener procurement policies. Non-PVC materials, which are often more readily recyclable and free of halogenated compounds, align with institutional sustainability goals and corporate social responsibility initiatives, adding an important non-clinical driver to the purchasing decision.

Clinical and Material Advantages

Beyond regulatory compliance, non-PVC IV bags offer distinct clinical and operational benefits. Their material composition generally provides superior compatibility with sensitive drug formulations, including certain lipids, taxanes, and other pharmaceuticals that can interact with or be absorbed by PVC. This reduces the risk of drug loss, potency reduction, and patient exposure to leached plasticizers. For healthcare facilities, this translates to enhanced patient safety, reduced medication waste, and greater flexibility in drug storage and administration.

Market Challenges and Restraints

The transition faces notable hurdles. A significant restraint is the higher unit cost of non-PVC bags compared to conventional PVC options. This cost differential can be a barrier for budget-constrained healthcare systems, particularly in price-sensitive markets, requiring a clear demonstration of long-term value through reduced complications and aligned sustainability benefits.

Furthermore, the entrenched, global manufacturing infrastructure for PVC medical devices presents a challenge to rapid market conversion. Supply chains for alternative polymers must achieve similar scale, reliability, and geographic penetration to meet global demand. Ensuring consistent material quality and navigating the complexities of validating new container-drug combinations also require ongoing investment from manufacturers.

Geographic Market Dynamics

North America is projected to maintain a leading market share, driven by a combination of stringent regulatory guidance, high awareness among healthcare providers, supportive reimbursement structures, and the presence of major market players. The region's focus on patient safety, coupled with proactive environmental policies in healthcare, creates a highly receptive environment for non-PVC alternatives. Europe follows a similar trajectory, heavily influenced by comprehensive regulations like the EU Medical Device Regulation (MDR) and strong environmental mandates. The Asia-Pacific region represents a high-growth opportunity, fueled by expanding healthcare infrastructure, increasing treatment volumes, and a gradual rise in regulatory standards and environmental awareness, though price sensitivity remains a more pronounced factor.

Competitive Landscape and Strategic Direction

The market is characterized by the presence of large, established medical device companies with extensive portfolios in infusion therapy. Competition centers on material science innovation, drug compatibility data, supply chain reliability, and the ability to offer a comprehensive range of non-PVC solutions. Strategic activities include investment in advanced polymer manufacturing, securing regulatory approvals for specific high-value applications (e.g., oncology, neonatology), and forming partnerships with drug manufacturers to develop compatible packaging systems. Success depends on demonstrating clinical superiority, achieving cost efficiencies at scale, and providing robust educational support to facilitate the transition for healthcare providers.

In conclusion, the non-PVC IV bags market is transitioning from a niche alternative to a mainstream standard, driven by an irreversible regulatory and environmental mandate. Its growth is structurally linked to the expansion of intravenous therapy across chronic disease management and the healthcare industry's commitment to safer, more sustainable practices. For industry experts, the critical path forward involves continuing to advance material technologies to improve performance and reduce costs, generating comprehensive clinical data to support broader adoption, and navigating the complex global regulatory landscape to ensure seamless market access. The long-term trajectory points toward non-PVC materials becoming the dominant standard for IV containment, reflecting the evolving priorities of patient care and environmental stewardship.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Non-PVC IV Bags Market Segmentation

By Type
Single Chamber
Multi-Chamber
By Material
Ethylene Vinyl Acetate (EVA)
Polypropylene (PP)
Copolyester Ether
By Capacity
Up to 50 ml
50 to 100 ml
Greater than 100 ml
By End-User
Hospitals
Specialty Clinics
Others
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. NON-PVC IV BAGS MARKET BY TYPE

5.1. Introduction
5.2. Single Chamber
5.3. Multi-Chamber

6. NON-PVC IV BAGS MARKET BY MATERIAL

6.1. Introduction
6.2. Ethylene Vinyl Acetate (EVA)
6.3. Polypropylene (PP)
6.4. Copolyester Ether

7. NON-PVC IV BAGS MARKET BY CAPACITY

7.1. Introduction
7.2. Up to 50 ml
7.3. 50 to 100 ml
7.4. Greater than 100 ml

8. NON-PVC IV BAGS MARKET BY END-USER

8.1. Introduction
8.2. Hospitals
8.3. Specialty Clinics
8.4. Others

9. NON-PVC IV BAGS MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. USA
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. Germany
- 9.4.2. France
- 9.4.3. United Kingdom
- 9.4.4. Spain
- 9.4.5. Others
9.5. Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Others
9.6. Asia Pacific
- 9.6.1. China
- 9.6.2. India
- 9.6.3. Japan
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Others